Vimpat (lacosamide, from UCB), an antiepileptic drug (AED), will be available the first week of June 2009. Vimpat tablets are indicated as adjunctive therapy for the treatment of partial-onset ...

Pfizer’s Lyrica Is The Top Selling Anti-Epileptic Drug, Followed By UCB’s Vimpat, and Keppra. Trefis. Pfizer’s Lyrica sales have been in the range of $4.8 to $5.2 billion over the last 5 years.

ATLANTA, Nov. 30, 2010 /PRNewswire/ -- New data on UCB's anti-epileptic drug (AED) Vimpat® (lacosamide) C-V will be presented at the 64th annual meeting of the American Epilepsy Society (AES ...

UCB's (UCBJF) Vimpat has been approved in the U.S. as monotherapy for the treatment of partial-onset seizures in epilepsy patients aged 17 years and above.

The Food and Drug Administration (FDA) has approved Vimpat (lacosamide; UCB) for the treatment of partial-onset seizures in pediatric patients ≥4 years old.As the safety of Vimpat injection has ...

The 405-patient phase 3 trial, published online in the journal Epilepsia, found that UCB’s Vimpat (lacosamide) resulted in “significantly” fewer partial-onset seizures in patients ages 16 to ...

BRUSSELS, Sept 3 (Reuters) - Belgian pharmaceutical group UCB said on Wednesday that the European Commission has approved its new epilepsy drug Vimpat. In June, the European Medicines Agency gave ...